Online inquiry

IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2510MR)

This product GTTS-WQ2510MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CALCRL gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001271751.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10203
UniProt ID Q16602
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2510MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10565MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ10527MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ12526MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ9399MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ7791MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ14919MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ4593MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ10154MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LBR-101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW